HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Vito M Campese Selected Research

Phenol (Carbolic Acid)

1/2009Regional expression of NAD(P)H oxidase and superoxide dismutase in the brain of rats with neurogenic hypertension.
7/2007A vitamin-E-fortified diet reduces oxidative stress, sympathetic nerve activity, and hypertension in the phenol-renal injury model in rats.
8/2006Oxidative stress mediates the stimulation of sympathetic nerve activity in the phenol renal injury model of hypertension.
9/2003A new model of neurogenic hypertension caused by renal injury: pathophysiology and therapeutic implications.
5/2003Chronic renal injury-induced hypertension alters renal NHE3 distribution and abundance.
2/2003Responses of proximal tubule sodium transporters to acute injury-induced hypertension.
8/2002Renal injury caused by intrarenal injection of phenol increases afferent and efferent renal sympathetic nerve activity.
6/2002Losartan reduces central and peripheral sympathetic nerve activity in a rat model of neurogenic hypertension.
2/2002Downregulation of neuronal nitric oxide synthase and interleukin-1beta mediates angiotensin II-dependent stimulation of sympathetic nerve activity.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Vito M Campese Research Topics

Disease

20Hypertension (High Blood Pressure)
01/2014 - 02/2002
9Chronic Renal Insufficiency
10/2014 - 03/2003
8Kidney Diseases (Kidney Disease)
04/2014 - 03/2003
7Chronic Kidney Failure (Chronic Renal Failure)
01/2017 - 06/2002
6Proteinuria
02/2012 - 03/2003
5Dyslipidemias (Dyslipidemia)
04/2014 - 01/2005
4Inflammation (Inflammations)
10/2014 - 01/2005
3Fibrosis (Cirrhosis)
08/2010 - 05/2009
2COVID-19
05/2021 - 01/2021
2Dehydration (Water Stress)
02/2021 - 01/2017
2Coronary Disease (Coronary Heart Disease)
10/2014 - 01/2013
2Overweight
12/2012 - 04/2006
2Glomerulonephritis
02/2012 - 04/2010
2Hyperkalemia
04/2010 - 12/2009
2Insulin Resistance
01/2010 - 04/2006
1Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome)
05/2021
1Hyperuricemia
02/2021
1Genetic Predisposition to Disease (Genetic Predisposition)
02/2021
1Infections
02/2021
1Hypotension (Low Blood Pressure)
01/2017
1Chronic Kidney Diseases of Uncertain Etiology
01/2017
1Transient Ischemic Attack
10/2014
1Diabetes Mellitus
10/2014
1Stroke (Strokes)
10/2014
1Acute Kidney Injury (Acute Renal Failure)
04/2014
1Type 2 Diabetes Mellitus (MODY)
12/2013
1Hematuria
02/2012
1IGA Glomerulonephritis (IGA Nephropathy)
02/2012
1Pyoderma Gangrenosum
02/2012
1Ulcerative Colitis
02/2012
1Graves Disease (Basedow Disease)
02/2012
1Drug-Related Side Effects and Adverse Reactions
07/2010
1Hyponatremia
05/2009
1Heart Failure
05/2009
1Liver Cirrhosis (Hepatic Cirrhosis)
05/2009
1Polycystic Kidney Diseases (Polycystic Kidney Disease)
05/2009
1Inappropriate ADH Syndrome (SIADH)
05/2009
1Ascites
05/2009
1Myocardial Infarction
05/2008
1Peripheral Vascular Diseases (Peripheral Vascular Disease)
05/2008
1Pathologic Constriction (Stenosis)
05/2008
1Cardiovascular Diseases (Cardiovascular Disease)
05/2008
1Angina Pectoris
05/2008
1Renal Hypertension
11/2006
1Essential Hypertension
04/2006

Drug/Important Bio-Agent (IBA)

9Phenol (Carbolic Acid)FDA Link
01/2009 - 02/2002
8Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
10/2014 - 03/2003
6AldosteroneIBA
08/2010 - 07/2005
5SodiumIBA
01/2014 - 07/2002
4SaltsIBA
01/2014 - 06/2002
4Angiotensin IIIBA
12/2009 - 09/2003
3LipidsIBA
04/2014 - 03/2003
3DiureticsIBA
01/2014 - 08/2007
3Antihypertensive Agents (Antihypertensives)IBA
12/2013 - 06/2002
3Proteins (Proteins, Gene)FDA Link
04/2010 - 11/2004
3Norepinephrine (Noradrenaline)FDA LinkGeneric
02/2003 - 06/2002
2Atorvastatin (Lipitor)FDA Link
10/2014 - 03/2003
2LDL CholesterolIBA
10/2014 - 04/2006
2CholesterolIBA
10/2014 - 01/2013
2Pharmaceutical PreparationsIBA
01/2014 - 07/2010
22- cyclohexylidenhydrazo- 4- phenyl- thiazoleIBA
12/2012 - 10/2008
2Coenzyme A (CoA)IBA
09/2011 - 03/2003
2Mineralocorticoid Receptors (Mineralocorticoid Receptor)IBA
08/2010 - 12/2009
2Reactive Oxygen Species (Oxygen Radicals)IBA
01/2009 - 08/2004
2Insulin (Novolin)FDA Link
05/2008 - 04/2006
2CytokinesIBA
10/2005 - 03/2005
2Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA
07/2005 - 03/2003
2Protein Isoforms (Isoforms)IBA
05/2003 - 02/2002
2Nitric Oxide Synthase (NO Synthase)IBA
07/2002 - 02/2002
2Losartan (Cozaar)FDA LinkGeneric
06/2002 - 02/2002
1GlucocorticoidsIBA
05/2021
1Heavy MetalsIBA
02/2021
1Immunoglobulin A (IgA)IBA
02/2012
1Antineutrophil Cytoplasmic Antibodies (ANCA)IBA
02/2012
1Peroxidase (Myeloperoxidase)IBA
02/2012
1Mineralocorticoid Receptor AntagonistsIBA
08/2010
1CreatinineIBA
04/2010
1Angiotensin Receptor AntagonistsIBA
01/2010
1Angiotensin Receptors (Angiotensin II Receptor)IBA
01/2010
1Angiotensin II Type 1 Receptor BlockersIBA
01/2010
1Telmisartan (Micardis)FDA Link
01/2010
1ReninIBA
12/2009
1AngiotensinsIBA
12/2009
1lixivaptanIBA
05/2009
1Vasopressins (Vasopressin)IBA
05/2009
14- ethoxymethylene- 2- phenyl- 2- oxazoline- 5- one (phOx)IBA
01/2009
1Superoxide DismutaseIBA
01/2009
1NADPH Oxidases (NAD(P)H oxidase)IBA
01/2009
1Enzyme Inhibitors (Inhibitors, Enzyme)IBA
08/2007
1AntioxidantsIBA
07/2007
1Vitamin EFDA LinkGeneric
07/2007
1Ouabain (G Strophanthin)IBA
11/2006
1Glucose (Dextrose)FDA LinkGeneric
04/2006
1AlbuminsIBA
04/2006

Therapy/Procedure

6Therapeutics
01/2021 - 07/2005
2Renal Dialysis (Hemodialysis)
01/2017 - 01/2010
2Denervation
01/2014 - 12/2013
2Nephrectomy
06/2002 - 02/2002
1Fluid Therapy (Oral Rehydration Therapy)
01/2017
1Peritoneal Dialysis
01/2010